A medicine can be legal to prescribe in the UK without being licensed for the reason a provider is offering it. That distinction sits at the centre of GLP-1 licensing status UK questions, and it is one worth checking before you compare monthly prices or complete an online questionnaire.

For weight-management treatment, a licence is not a marketing badge or a guarantee that a medicine is suitable for every person. It sets out the specific use the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised, including the patient group, clinical circumstances and product information. A UK-registered prescriber must still decide whether prescribing is appropriate after a proper assessment.

What “licensed” actually means

A licensed medicine has a UK marketing authorisation. Its official product information, often called the Summary of Product Characteristics, describes what it is authorised to treat, who it is intended for, when it should not be used and the safety information clinicians need to consider.

For medicines commonly discussed as GLP-1 treatments, the key question is not simply whether the active ingredient has a licence. Ask: is this particular product licensed for weight management, or for another condition such as type 2 diabetes? Products containing related medicines can have different licences, even where their names, delivery method or active ingredients appear similar.

Tirzepatide is often grouped into GLP-1 discussions because it acts on the GLP-1 pathway, but it is technically a dual GIP and GLP-1 receptor agonist. That technical point does not change the consumer check: look at the licence for the named product and its intended use, not a broad treatment category.

A licence also does not mean a provider can skip its clinical responsibilities. Prescription-only medicines require a prescription from an appropriate prescriber. An online form may be part of an assessment, but it is not a substitute for the provider reviewing the information, asking follow-up questions where needed and making an individual prescribing decision.

GLP-1 licensing status UK for weight management

The following is a high-level guide to the distinction consumers are most likely to encounter. Licensing information can change, and individual eligibility is for the prescriber to assess against the current product information.

| Medicine or product type | Typical UK licensed purpose | What to check before joining a provider | |---|---|---| | Semaglutide product licensed for weight management | Weight management alongside dietary and physical-activity measures, for defined adult groups | Whether the provider is offering the weight-management licensed product rather than a diabetes-only product | | Tirzepatide product licensed for weight management | Weight management alongside dietary and physical-activity measures, for defined adult groups | The current eligibility criteria, monitoring approach and total ongoing cost | | Liraglutide product licensed for weight management | Weight management alongside dietary and physical-activity measures, for defined adult groups | Whether it remains suitable to the provider’s clinical pathway and what support is included | | Products licensed for type 2 diabetes only | Blood-glucose management in type 2 diabetes, subject to their own product licences | Whether weight management is being presented as an off-label use and how the prescriber justifies it |

The exact licensed population is not simply “anyone who wants to lose weight”. Product licences normally include body mass index thresholds and, in some cases, weight-related health conditions. A provider should not make eligibility sound automatic from a headline figure alone. Your medical history, current medicines and clinical information can all affect whether a prescriber is able to prescribe.

Be cautious with vague phrases such as “MHRA approved GLP-1s” when there is no product name or indication beside them. The wording may be technically true in a narrow sense while leaving out the point that matters: the approved use of the medicine being supplied.

Licensed use versus off-label prescribing

Off-label prescribing means a licensed medicine is prescribed outside the terms of its licence. This might relate to the condition being treated, the patient group or another detail of use. It is not automatically unlawful, nor does it necessarily mean poor care. In UK practice, it can be clinically justified when a prescriber has considered the evidence, alternatives and the person’s circumstances.

But it should never be disguised as licensed weight-management treatment. If a provider supplies a product that is licensed for diabetes and is discussing it for weight management, its information should be clear about that distinction. The prescriber takes responsibility for the decision and should be able to explain the basis for it as part of the clinical process.

For consumers, this is less about trying to second-guess a clinician and more about avoiding misleading comparisons. Two providers can appear to sell the same thing at very different prices when one is quoting a different product, different indication, different service level or a limited introductory offer.

A lower monthly figure is not automatically poor value, and a higher one is not automatically safer. Compare what is actually being prescribed, whether the stated use aligns with the product licence, and what clinical service is included throughout treatment.

A licence is not the same as provider regulation

Medicine licensing, prescriber regulation and pharmacy regulation are separate checks. A legitimate-looking website can talk about an MHRA-authorised medicine while being unclear about who assesses patients, who writes prescriptions or where medicines are dispensed.

Never use a provider that cannot clearly confirm these basics:

  • the identity and UK registration of the clinician or prescribing service;
  • the regulated pharmacy that dispenses and sends the medicine;
  • the provider’s relevant healthcare regulation, such as CQC registration in England where applicable; and
  • the full commercial terms, including consultation, delivery, follow-up and cancellation arrangements.

For services outside England, the relevant healthcare regulator may differ. The important point is that the provider should be open about its regulatory set-up rather than relying on generic claims that it is “fully approved”.

A regulated pharmacy does not, by itself, tell you whether the consultation process is adequate. Equally, a polished clinic website does not prove the medicine comes from a properly regulated pharmacy. Check both sides of the service.

Questions that expose unclear offers

Before paying, ask the provider which named medicine and presentation it expects to prescribe if clinically appropriate. Ask whether that product is licensed in the UK for weight management, and whether the quoted price covers the medicine, clinical assessment, follow-up reviews, delivery and any administration or dispensing charges.

You should also ask what happens if the prescriber decides treatment is unsuitable. Some providers charge for the clinical assessment even where no prescription is issued; others offer a refund under stated conditions. Neither approach is inherently wrong, but the policy should be visible before you provide payment details.

If a service uses a subscription, check how often it renews, whether prices change at later stages, how cancellation works and whether support or reviews are included. The first-month price is rarely the useful comparison. The cost over several months, on the product and service you may actually receive, is the figure that matters.

Red flags worth taking seriously

Walk away from websites offering prescription-only GLP-1 medicines without a meaningful clinical assessment, promising guaranteed approval, or refusing to name the pharmacy and prescriber. The same applies to sellers presenting a product as licensed for weight management while avoiding a direct answer about its named indication.

Be particularly wary of social-media sellers, payment requests to personal accounts, products without patient information, or claims that a medicine can be supplied because it is “the same ingredient” as a licensed alternative. Similarity is not the same as being the same authorised product, supplied through the same regulated route.

You do not need to become an expert in pharmaceutical regulation to compare providers well. You only need clear answers on the medicine, its licensed purpose, the clinician, the pharmacy and the total commitment. If those answers are hard to obtain before payment, that is useful information in itself.